LSX

By offering free sequencing and embracing radical openness with global partners, Regeneron Genetics Center has gathered over 3 million samples, leading to the identification of over 30 drug targets now in Regeneron’s pipeline.

Corporate venture arms can be powerful growth partners, but founders who don’t take time to understand them risk missing their greatest value.

Pharma business development teams are adapting M&A and licensing strategies amid market volatility and looming patent cliffs.

Strategic partnerships and disciplined spending are emerging as key survival tools in challenging funding environment.

Altoida CEO Mark Jones has high hopes that the company’s digital assessment tool will be approved by the FDA to be used along with blood biomarker testing by primary care doctors to help predict Alzheimer’s disease before patients show symptoms.

Altoida CEO Marc Jones spoke with Medtech Insight about the company’s investigational digital screening tool for Alzheimer’s and the dire need for better, more accessible precision neurology diagnostics as the global population ages, neurologist shortages worsen, and groundbreaking Alzheimer’s drugs change the treatment paradigm.

Leaders from Eli Lilly and Vertex Pharmaceuticals, 9amHealth, Features Capital, and accelerator PharmStars discussed the convergence of biopharma, medtech and healthtech, and what is needed to achieve health care transformation, in an LSX World Congress USA panel.